-
Sector Analysis
Hepatocellular Carcinoma (HCC): Epidemiology Report and Forecast to 2035
Why Does Hepatocellular Carcinoma Epidemiology Matter? Hepatocellular carcinoma (HCC) is the most common primary liver cancer, accounting for approximately 90% of primary liver cancers. Understanding the size and characteristics of the HCC patient population is important for assessing disease burden and planning therapeutic strategies. HCC has a high mortality rate and is the third leading cause of cancer deaths annually worldwide. This epidemiology model provides a 10-year forecast of diagnosed incident cases, five-year diagnosed prevalent cases, and all-time diagnosed prevalent...
-
Sector Analysis
Against the Clock: the Bundibugyo Ebola Outbreak
Research into new Ebola vaccines and therapeutics, ranging from prophylaxis to post-exposure prophylaxis treatment candidates, are being fast-tracked, using similar mechanisms to fast-tracked COVID-19 trials. Even so, there are legitimate concerns that the Bundibugyo strain of the Ebola virus is moving faster than the response of technology developers, regulators, governments, and international organizations.
-
Sector Analysis
Hepatitis C Virus: Epidemiology Report and Forecast to 2035
Hepatitis C is an inflammatory liver disease caused by the hepatitis C virus (HCV). HCV primarily spreads through direct blood contact, which can happen via needle/syringe sharing in people who inject drugs, unscreened blood transfusions and unsterilized medical equipment, and sexual contact involving blood. Additionally, vertical transmission of HCV can occur (Public Health England, 2018). Many people with hepatitis C are asymptomatic and unaware that they have the infection, with only approximately a quarter of patients exhibiting symptoms, including fatigue,...
-
Sector Analysis
Epilepsy: Epidemiology Report and Forecast to 2035
Why Does Epilepsy Epidemiology Matter? Epilepsy is one of the most widespread neurological disorders globally, characterized by recurrent, unpredictable seizures caused by abnormal electrical activity in the brain. Understanding the size and composition of the diagnosed patient population is critical for assessing future healthcare and treatment needs. In the seven major markets (7MM), active diagnosed prevalent cases of epilepsy are forecast to increase from 6.2 million in 2025 to 6.5 million in 2035, representing an annual growth rate (AGR) of...
-
Sector Analysis
New Drug Approvals and Their Contract Manufacture: 2026 Edition
This report is the 16th edition of our long-running analysis of the CMO industry, using the FDA's NDA approvals as the primary indicator of performance. New Drug Approvals and Their Contract Manufacture (formerly called "CMO Scorecard") is critical for benchmarking the performance of the contract manufacturing organization (CMO) industry and the relative performance of major CMOs. This year's edition includes a discussion of how the US onshoring push is creating billion-dollar manufacturing investments.
-
Sector Analysis
Tackling Drug Prices in the US (White Paper)
GlobalData is pleased to announce the release of a special white paper covering the latest disruptions in US drug pricing. Use this report to: Learn more about the US healthcare system in general, medicines' pricing and reimbursement, and the latest events disrupting the pharmaceutical market. Understand and evaluate the impact the latest US reforms will have on medicines' prices, reimbursement and market access worldwide
-
Thematic Analysis
State of the Biopharmaceutical Industry 2026 (Mid-Year Update) Edition
Report Value Proposition – Why This Matters for You The biopharmaceutical industry enters 2026 facing a rapidly evolving landscape shaped by artificial intelligence adoption, regulatory changes, pricing pressures, geopolitical uncertainty, and increasing competition for innovation leadership. This report helps stakeholders understand the trends that will define biopharma performance over the next 12 months, covering R&D productivity, commercialization strategies, market access challenges, investment sentiment, and emerging growth opportunities. Drawing on industry surveys, proprietary market intelligence, and expert analyst insight, the report...
-
Sector Analysis
Bio/Pharmaceutical Outsourcing Report, May 2026
The Bio/Pharmaceutical Outsourcing Report is a monthly analysis of news and trends affecting pharmaceutical Contract Manufacturing Organizations (CMOs). It includes in-depth analyses of the latest business conditions, lists new outsourcing contracts, assesses the latest opportunities and threats for manufacturers, and identifies recent mergers, acquisitions, and financing among CMOs. It also updates readers on facility-level news, such as planned site openings and closures, Good Manufacturing Practice (GMP) inspections, and investments in technology and equipment.
-
Sector Analysis
Nasal Polyps (Nasal Polyposis) and CRSwNP (Chronic Rhinosinusitis with Nasal Polyps): Market View, Current and Future Competitive Landscape
This report provides a data-driven overview of the current and future competitive landscape in Nasal Polyps (Nasal Polyposis) and CRSwNP (Chronic Rhinosinusitis with Nasal Polyps) Therapeutics. In 2025, there were more than 5.15 million diagnosed incident cases of nasal polyps and CRSwNP in the 16 countries covered in GlobalData’s epidemiology forecast. The current treatment landscape for nasal polyps primarily involves intranasal corticosteroids, oral corticosteroids for severe cases, and functional endoscopic sinus surgery for patients unresponsive to medical therapy, with biologics...